The Most Comprehensive Breast Cancer Preclinical Platform
Crown Bioscience offers a complete portfolio of breast cancer models and services to help drug developers move from early screening to in vivo validation with confidence.
Crown Bioscience's breast cancer PDX collection includes models representing key clinical and molecular subtypes, including triple-negative, luminal, HER2-positive, ER-positive, and rare histologies.
Crown Bioscience supports breast cancer ADC development with models selected by target expression, subtype, histology, and molecular profile to evaluate efficacy, resistance, and pharmacodynamic biomarkers.
Matched breast cancer PDXO and PDX pairs from the same patient let you screen in vitro and confirm in vivo in genetically concordant models, with organoid studies completing in weeks.
Crown Bioscience's TNBC models support preclinical evaluation of ADCs, targeted therapies, DNA damage response inhibitors, chemotherapy combinations, and immuno-oncology strategies in aggressive breast cancer biology.
Crown Bioscience's breast cancer organoid models enable rapid in vitro screening, combination testing, and biomarker-linked response analysis using patient-derived systems with strong translational relevance.
Crown Bioscience helps researchers select breast cancer models using molecular, pathology, and clinical annotations, including RNA expression, mutation, copy number, IHC, HRD, MSI, and treatment history where available.
Benchmark Your Program Against the Evolving Breast Cancer Treatment Landscape
Breast cancer drug development is increasingly shaped by ADCs, targeted therapies, endocrine therapy combinations, chemotherapy backbones, and biomarker-defined patient populations.
Crown Bioscience supports benchmarking across clinically relevant breast cancer models with data from ADCs and standard-of-care agents, including HER2-directed ADCs, TROP2-directed ADCs, taxanes, endocrine therapies, PARP inhibitors, CDK4/6 inhibitors, HER2-targeted therapies, and immuno-oncology agents.
Utilize our breast cancer PDX, CDX, syngeneic, and organoid platforms to compare response patterns, evaluate combinations, understand resistance, and build a stronger translational data package for internal decision-making and external stakeholders.
AACR 2026 Poster
Paired Breast Cancer PDX-PDXO Models Serve an Integrated Preclinical Platform for High-Throughput Payload Screening and ADC drugs development
Download Now
Drawing on Crown Bioscience’s breast cancer expertise and portfolio of 300+ models, our speakers discuss how to connect early screening with in vivo validation and biomarker-informed therapeutic decision-making.
Mariusz Madej, PhD and David Vallerand, PhD highlight how integrating breast cancer organoids, in vivo models, and biomarker data enables:
- Rapid Translational Screening: Using patient-derived and PDX-derived breast cancer organoids for scalable in vitro screening, responder analysis, and evaluation of ADCs and targeted therapies.
- Predictive In Vivo Validation: Leveraging PDX, CDX, syngeneic, and tumor homograft models to assess therapeutic efficacy across diverse breast cancer settings.
- Biomarker-Informed Model Selection: Combining mutation, expression, and protein data—including ER, PR, HER2, and ADC-relevant targets—to select models and guide targeted therapy, ADC, and immuno-oncology strategies.
Matched patient-derived organoids enable rapid in vitro screening and can be paired with corresponding PDX models for stronger translational continuity.
Our Breast Cancer PDX collection supports in vivo efficacy studies, resistance modeling, and biomarker research across clinically relevant molecular subtypes.
.webp)
GEMMs support mechanistic studies, pathway biology, and resistance research in genetically defined breast cancer settings.
Breast Cancer Resources and Data
